Risk factor
Very high price volatility
Profitability factor
Strong margins and returns
About
Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers pre-clinical contract research and development services for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, tissue research, assays, molecular pharmacology,...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is underpriced on P/E, 'expensive' on EV/EBITD
Target Price
The average target price of GUBRA.CO is 528 and suggests 18% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell